-
The Artificial Intelligence Era in Health Economic Modeling
Sep 9, 2025, 16:22 PM -
Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management
Sep 9, 2025, 16:22 PM -
HTA Requirements for Medical Technologies in Germany
Sep 9, 2025, 16:22 PM -
Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia
Sep 9, 2025, 16:22 PM -
Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Sep 9, 2025, 16:22 PM -
Deep Real-World Analysis of Patients With Myelofibrosis Using Natural Language Processing and Machine Learning: A Methods Description
Sep 9, 2025, 16:22 PM -
Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom
Sep 9, 2025, 16:22 PM -
Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective
Sep 9, 2025, 16:22 PM -
MCDA Tool Adoption in Egypt: Room for Sustainability and Accessibility
Sep 9, 2025, 16:22 PM -
Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma
Sep 9, 2025, 16:22 PM -
Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers
Sep 9, 2025, 16:22 PM -
A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Societal Perspectives in the EU Joint Clinical Assessment Framework and in EU-27 Health Technology Assessment Guidelines
Sep 9, 2025, 16:22 PM -
Assessment of Newly Developed Medication Adherence Tool in Rural Community Pharmacies
Sep 9, 2025, 16:22 PM -
The Impact of Menopausal Hormone Therapy on Productivity and Health Care Utilization in Women: A Finnish Claims Database Study
Sep 9, 2025, 16:22 PM -
Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in France: A Use Case in Rare Diseases
Sep 9, 2025, 16:22 PM -
Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data
Sep 9, 2025, 16:22 PM -
Efficacy and Safety of Modern Biologics Compared to Conventional Therapies in AQP-4 Positive Neuromyelitis Optica Spectrum Disorder: A Fully AI-Automated Targeted Literature Review
Sep 9, 2025, 16:22 PM
